PODD · Insulet Corp

Insulet Corporation (NASDAQ: PODD) (“Insulet” or the “Company”), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced the appointment of Mike Panos as Executive Vice President, Chief Commercial Officer, effective immediately. In this role, Mr. Panos will lead Insulet’s global commercial organization, reporting to President and Chief Executive Officer Ashley McEvoy. He will also be a member of the Executive Leadership Team. “We have a significant growth opportunity in front of us, driven by strong clinical outcomes, customer-centric innovation, and expanding global adoption of automated insulin delivery as the standard of care in both type 1 and type 2 diabetes,” said Ashley McEvoy, Insulet President and Chief Executive Officer. “We are implementing thoughtful strategies to strengthen our capabilities and structure to capture this opportunity and are thrilled to welcome Mike to Insulet. His expertise in building high-performing

Medical Device Correction impacts only specific lots of Omnipod® 5 Pods Customers can visit omnipod.com/check-pods to check lot numbers and request replacement Pods at no cost All other Omnipod® 5 Pods and Omnipod® products remain safe to use Insulet Corporation (NASDAQ: PODD) (“Insulet” or the “Company”) today initiated a voluntary Medical Device Correction for specific lots of Omnipod® 5 Pods after identifying a manufacturing issue through its ongoing product monitoring. This action applies to specific identified lots distributed in the United States, and all other Omnipod® 5 Pods and Omnipod® products remain safe to use. Insulet identified that certain Pods from specific lots may have a small tear in the internal tubing that delivers insulin. If this occurs, insulin may leak inside the Pod instead of being fully infused into the body as intended. If insulin is not delivered properly, users may experience high blood glucose levels due to under-delivery of insulin. In the most severe

Outcomes from EVOLUTION 2 study include 68% time in range with no boluses Diverse multicenter feasibility study highlights the promise of future Omnipod innovation to address unmet needs, improve outcomes, and redefine user and clinician experience Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, has shared new clinical evidence related to the development of its first fully closed-loop (FCL) A automated insulin delivery (AID) system for type 2 diabetes. “Developing and bringing to market a fully closed-loop AID system for people with type 2 diabetes—one that delivers therapy effortlessly and adapts automatically with no mealtime interactions or adjustments—is more than evolutionary; it’s revolutionary,” said Dr. Trang Ly, MBBS, FRACP, PhD, Senior Vice President and Chief Medical Officer. “Our latest EVOLUTION study brings us another important step closer to addressing significant

Fully Closed-Loop System Feasibility Study to be presented at Insulet Symposium and in e-Poster during ATTD 2026 Real World Evidence of Settings Optimization in Omnipod 5 Users will also be shared Other activities include immersive multi-media education HUB, hands-on Omnipod product demonstrations led by clinical experts, and live podcast recordings Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products , will present new clinical evidence related to its first fully closed-loop (FCL) automated insulin delivery (AID) system for type 2 diabetes (T2D) at the 19 th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD), taking place March 11 – 14, 2026 in Barcelona, Spain, and online. “At Insulet, our mission is to transform the lives of people with diabetes, and our recent work in developing a fully closed-loop system for people with type 2 diabetes is a major

Fourth Quarter 2025 Revenue Increase of 31% (29% Constant Currency1) and Full Year 2025 Revenue Increase of 31% Year-Over-Year (30% Constant Currency) Represents 10th Consecutive Year of 20% or More Constant Currency Revenue Growth Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced financial results for the three months and full year ended December 31, 2025. Fourth Quarter Financial Highlights: Revenue of $783.8 million, up 31.2%, or 29.0% in constant currency, and exceeded the high end of the Company’s guidance range of 25% to 28% in constant currency Total Omnipod revenue of $781.8 million, rose 33.5%, or 31.3% in constant currency U.S. revenue of $567.8 million, increased 28.0% International revenue of $214.0 million, increased 50.7%, or 41.7% in constant currency Drug Delivery revenue totaled $2.0 million Gross margin of 72.5%, up 40 basis points over

The Omnipod 5 Automated Insulin Delivery System is now commercially available in Saudi Arabia, Kuwait, Qatar, and the United Arab Emirates, compatible with Abbott and Dexcom continuous glucose sensors Inaugural launch of Omnipod Discover data management platform aims to lessen the burdens on healthcare providers and users, streamlining diabetes information into meaningful insights Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced its transformative Omnipod 5 Automated Insulin Delivery (AID) System is now available in the Middle East – including Saudi Arabia, Kuwait, Qatar, and the United Arab Emirates (UAE). The Company is making the announcement at the 16 th edition of the Emirates Diabetes and Endocrine Congress (EDEC) in Dubai. “We’re proud to bring Omnipod 5 to a region where the unmet need is great 1 . These launches build on our significant momentum as we

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced it will report financial results for the fourth quarter and full year of 2025 on February 18, 2026, before the opening of the financial markets. In connection with the release, management will host a conference call that day at 8:00 a.m. (Eastern Time). The link to the live call will be available on the Investor Relations section of the Company's website at investors.insulet.com , “Events and Presentations,” and will be archived for future replay. You may also access the live call by dialing (888) 770-7129 for domestic callers, or (929) 203-2109 for international callers; the passcode is 5904836. About Insulet Corporation: Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its

The Company will host a Digital Health Track panel discussion exploring how human-first design and intelligent automation are transforming chronic care into everyday freedom Insulet’s immersive booth will showcase how tubeless, automated insulin delivery transforms the lives of people with diabetes by reducing mental load and improving health outcomes Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced its debut at Consumer Electronics Show (CES) 2026, where the Company will showcase its vision for liveable technology through an immersive booth experience, expert panel session, and media demonstrations. Liveable technology reflects Insulet’s philosophy for the future of connected health: effortless, intelligent systems that support daily life. As digital health accelerates, people increasingly want technology that lightens the mental load and surfaces insights only when